Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) saw unusually-high trading volume on Wednesday . Approximately 3,668,138 shares changed hands during trading, an increase of 68% from the previous session’s volume of 2,186,278 shares.The stock last traded at $7.05 and had previously closed at $6.34.

FOLD has been the topic of a number of analyst reports. Goldman Sachs Group Inc. initiated coverage on Amicus Therapeutics in a research note on Wednesday, March 30th. They set a “neutral” rating and a $10.00 price objective on the stock. Chardan Capital boosted their price objective on Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, April 12th. Robert W. Baird initiated coverage on Amicus Therapeutics in a research note on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price objective on the stock. Bank of America Corp. initiated coverage on Amicus Therapeutics in a research note on Wednesday, May 18th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Leerink Swann reiterated an “outperform” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, June 1st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $12.19.

The company’s 50-day moving average is $5.93 and its 200 day moving average is $6.85. The stock’s market cap is $905.86 million.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.01. Equities research analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

In other news, General Counsel Ellen Rosenberg bought 15,000 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, June 2nd. The stock was bought at an average price of $7.67 per share, for a total transaction of $115,050.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

A number of institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its position in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,754 shares during the period. ProShare Advisors LLC increased its stake in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares in the last quarter. Swiss National Bank increased its stake in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares in the last quarter. TD Asset Management Inc. increased its stake in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares in the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.